ERCC1 and non-small cell lung carcinoma: It was concluded that NSCLC patients with completely resected ERCC1 negative tumors seem to derive a substantial benefit from adjuvant cisplatin-based chemotherapy compared to those with resected ERCC1 positive tumors.